Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
CNTX
Stock Latest News
Ratings
Analyst Reiterates Buy on Context Therapeutics, Maintains $4 Price Target Amid Promising CTIM‑76 Data and Compelling Valuation
15d ago
CNTX
Premium
The Fly
Context downgraded to Market Perform from Outperform at LifeSci Capital
20d ago
CNTX
Premium
The Fly
Context Therapeutics price target lowered to $3 from $4 at Citizens
20d ago
CNTX
Premium
Ratings
Analyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver
20d ago
CNTX
Premium
Ratings
Analyst Reiterates Buy on CTI with Unchanged $5 Price Target, Citing CTIM-76 Differentiation and Strategic Focus on CT-202
20d ago
CNTX
Premium
The Fly
Context Therapeutics reports Q2 EPS (15c), consensus (9c)
21d ago
CNTX
Premium
Company Announcements
Context Therapeutics Highlights Progress in T Cell Engager Pipeline
21d ago
8K
CNTX
Premium
Company Announcements
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
26d ago
8K
CNTX
Premium
Company Announcements
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst
2M ago
CNTX
Premium
Company Announcements
Context Therapeutics Shareholders Approve Stock Increase and Directors
2M ago
8K
CNTX
Premium
The Fly
Context Therapeutics price target lowered to $4 from $8 at Maxim
2M ago
CNTX
Premium
Ratings
Boris Peaker Reiterates Buy on Context Therapeutics, Maintains $7 Price Target on Promising CTIM-76 Data and Attractive Risk/Reward
2M ago
CNTX
Premium
The Fly
Context Therapeutics selloff brings buying opportunity, says JonesResearch
2M ago
CNTX
ZYME
Premium
Ratings
Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook
2M ago
CNTX
Premium
The Fly
Context stock reaction ‘overdone’ after CTIM-76 data, says H.C. Wainwright
2M ago
CNTX
Premium
Company Announcements
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
2M ago
8K
CNTX
Premium
The Fly
Context Therapeutics announces ‘positive’ results from Phase 1 CTIM-76 trial
2M ago
CNTX
Premium
Ratings
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
3M ago
CNTX
Premium
Ratings
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
3M ago
CNTX
Premium
Company Announcements
Context Therapeutics Secures Full Rights to Antibody Assets
3M ago
8K
CNTX
Premium
The Fly
Context Therapeutics enters license agreement amendment with BioAtla
3M ago
BCAB
CNTX
Premium
Ratings
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
4M ago
CNTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
